Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F Archer

Showing results (141-150 of 175) with videos related to

Pageof 18
Sort By:
The Journal of Steroid Biochemistry and Molecular Biology|August 21, 2015
Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administrationYuyong Ke, Fernand Labrie, Renaud Gonthier, et al.
Contraception|April 17, 2022
Evaluation of ovulation and safety outcomes in a multi-center randomized trial of three 84 day ulipristal acetate regimensCarolyn L Westhoff, David F Archer, Kurt Barnhart, et al.
Contraception|December 24, 2005
FemCap with removal strap: ease of removal, safety and acceptabilityChristine K Mauck, Debra H Weiner, Mitchell D Creinin, et al.
Fertility and Sterility|June 6, 2017
Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept studyDavid F Archer, Elizabeth A Stewart, Rita I Jain, et al.
Menopause (New York, N.Y.)|June 23, 2009
Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal womenDavid F Archer, JoAnn V Pinkerton, Wulf H Utian, et al.
Menopause (New York, N.Y.)|May 14, 2015
Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal womenDavid J Portman, Fernand Labrie, David F Archer, et al.
Contraception|June 23, 2004
Single and multiple exposure tolerance study of polystyrene sulfonate gel: a phase I safety and colposcopy studyChristine K Mauck, Debra H Weiner, Susan A Ballagh, et al.
F&S Reports|September 23, 2021
Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosisOzgul Muneyyirci-Delale, David F Archer, Charlotte D Owens, et al.
Journal of Women'S Health (2002)|September 28, 2021
Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine FibroidsElizabeth A Stewart, David F Archer, Charlotte D Owens, et al.
Menopause (New York, N.Y.)|January 6, 2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopauseFernand Labrie, David F Archer, William Koltun, et al.
Pageof 18

Showing results (141-150 of 175) with videos related to

Sort By:
Pageof 18
The Journal of Steroid Biochemistry and Molecular Biology|August 21, 2015
Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administrationYuyong Ke, Fernand Labrie, Renaud Gonthier, et al.
Contraception|April 17, 2022
Evaluation of ovulation and safety outcomes in a multi-center randomized trial of three 84 day ulipristal acetate regimensCarolyn L Westhoff, David F Archer, Kurt Barnhart, et al.
Contraception|December 24, 2005
FemCap with removal strap: ease of removal, safety and acceptabilityChristine K Mauck, Debra H Weiner, Mitchell D Creinin, et al.
Fertility and Sterility|June 6, 2017
Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept studyDavid F Archer, Elizabeth A Stewart, Rita I Jain, et al.
Menopause (New York, N.Y.)|June 23, 2009
Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal womenDavid F Archer, JoAnn V Pinkerton, Wulf H Utian, et al.
Menopause (New York, N.Y.)|May 14, 2015
Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal womenDavid J Portman, Fernand Labrie, David F Archer, et al.
Contraception|June 23, 2004
Single and multiple exposure tolerance study of polystyrene sulfonate gel: a phase I safety and colposcopy studyChristine K Mauck, Debra H Weiner, Susan A Ballagh, et al.
F&S Reports|September 23, 2021
Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosisOzgul Muneyyirci-Delale, David F Archer, Charlotte D Owens, et al.
Journal of Women'S Health (2002)|September 28, 2021
Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine FibroidsElizabeth A Stewart, David F Archer, Charlotte D Owens, et al.
Menopause (New York, N.Y.)|January 6, 2016
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopauseFernand Labrie, David F Archer, William Koltun, et al.
Pageof 18